MesenCure is under clinical development by Bonus BioGroup and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MesenCure’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MesenCure overview

MesenCure is under development for the treatment of pneumonia, acute and life-threatening respiratory distress caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other  inflammations. It is administered through intravenous transfusions. The drug candidate comprises of activated mesenchymal stromal cells (MSCs) that are isolated from the adipose tissue of healthy donors.

Bonus BioGroup overview

Bonus BioGroup, formerly Oceania advanced industries is a biotechnology company that supplies tissue-engineered viable bone grafts. The company operates in the field of tissue engineering and live bone transplantation. Its products include BonoFill injectable bone graft that is suitable for bone repair applications including jawbone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Bonus BioGroup’s products pipeline comprises bone grafts for maxillofacial and orthopedic applications; combined bone and cartilage grafts for joint repair; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company develops tissue-regenerating bone grafts from cells derived from the patient’s fat tissue for the treatment of skeletal disorders such as cartilage and bone-related arthritis, and various types of bone and joint trauma. Bonus BioGroup is headquartered in Haifa, Israel.

For a complete picture of MesenCure’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.